Since then, Riamilovir is the second yet the main name of the drug produced at the Urals Medsintez plant.

INN is a unique name, which is recognized worldwide and is public property. Being unique, INN features spelling and sounding that differs from other names, so that it is impossible to confuse it with other common names.

Medsintez filed an application with WHO for the assignment of a non-proprietary name to its new pharmaceutical substance, Triazavirin, as far back as in 2016. Names to be granted the INN status are selected by the World Health Organization based on recommendations of experts from the WHO's Expert Group of Advisors for International Pharmacopoeia and Pharmaceuticals. INNs are selected only for certain, specific substances which can be uniquely defined using a chemical name (or formula). The INN program's principle is not to select names for mixtures of various substances. INNs are not selected for plant-based substances (herbal medicines) and homeopathic remedies. 

"As part of the consideration process, the expert group paid attention to two fundamental aspects: whether the substance is really new (the novelty in relation to previously filed applications for similar substances was checked), whether the new substance is a pharmaceutically active agent and whether the antiviral effect had been proven (provided data on the antiviral mechanism were studied). As a result of the review, the experts selected the Riamilovir name,” comments V. Lukshin, Director General of the Ural Center for Biopharmaceutical Technologies, the resident of the Skolkovo Foundation and the developer of the drug.

WHO Drug Information, Vol. 32, No. 1, 2018 Recommended INN: List 79